2186 Stock Overview
An investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2186 from our risk checks.
Luye Pharma Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.62 |
| 52 Week High | HK$4.00 |
| 52 Week Low | HK$2.34 |
| Beta | 0.85 |
| 11 Month Change | -14.38% |
| 3 Month Change | -5.42% |
| 1 Year Change | -34.17% |
| 33 Year Change | -31.23% |
| 5 Year Change | -57.33% |
| Change since IPO | -60.90% |
Recent News & Updates
Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares
Sep 25
Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?
Aug 29Recent updates
Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares
Sep 25Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?
Aug 29Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors
Jun 19We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed
May 21Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden
Apr 26Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?
Feb 29Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S
Jan 09Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt
Dec 19A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)
Nov 24Is Luye Pharma Group (HKG:2186) A Risky Investment?
Sep 12Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price
Aug 17Is Luye Pharma Group (HKG:2186) Using Too Much Debt?
May 10We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt
Sep 20Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook
Apr 06Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares
Mar 17Shareholder Returns
| 2186 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -3.3% | 0.8% | 0.4% |
| 1Y | -34.2% | -7.5% | 12.0% |
Return vs Industry: 2186 underperformed the Hong Kong Pharmaceuticals industry which returned -7.5% over the past year.
Return vs Market: 2186 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 2186 volatility | |
|---|---|
| 2186 Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2186 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2186's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 5,234 | Dian Bo Liu | www.luye.cn |
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Apleek Transdermal Patch for contraception; Rivastigmine Transdermal Patch for the treatment of Alzheimer’s disease; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders.
Luye Pharma Group Ltd. Fundamentals Summary
| 2186 fundamental statistics | |
|---|---|
| Market cap | HK$9.86b |
| Earnings (TTM) | HK$828.04m |
| Revenue (TTM) | HK$6.79b |
11.9x
P/E Ratio1.5x
P/S RatioIs 2186 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2186 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.31b |
| Cost of Revenue | CN¥1.97b |
| Gross Profit | CN¥4.34b |
| Other Expenses | CN¥3.57b |
| Earnings | CN¥770.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 68.73% |
| Net Profit Margin | 12.20% |
| Debt/Equity Ratio | 66.6% |
How did 2186 perform over the long term?
See historical performance and comparison